CNBX (CNBX Pharmaceuticals) E10: $0.00 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CNBX Pharmaceuticals E10?

CNBX Pharmaceuticals CNBX +33.33% E10 is $0.00 as of May. 2026. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

CNBX Pharmaceuticals's adjusted earnings per share data for the three months ended in May. 2026 was $0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.00 for the trailing ten years ended in May. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of CNBX Pharmaceuticals was 23.30% per year. The lowest was -0.30% per year. And the median was 9.35% per year.

As of today (2026-08-27), CNBX Pharmaceuticals's current stock price is $0.0002. CNBX Pharmaceuticals's E10 for the quarter that ended in May. 2026 was $0.00. CNBX Pharmaceuticals's Shiller PE Ratio of today is .


CNBX Pharmaceuticals  (OTCPK:CNBX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


CNBX Pharmaceuticals E10 Related Terms


CNBX Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for CNBX Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNBX Pharmaceuticals E10 Chart

CNBX Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.28 -3.85 -3.50 0.00 0.00

CNBX Pharmaceuticals Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CNBX vs SIGY, LIPO, CARM: E10 Comparison

For the Biotechnology subindustry, CNBX Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's Shiller PE Ratio falls into.



CNBX Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CNBX Pharmaceuticals's adjusted earnings per share data for the three months ended in May. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of May. 2026 (Change)*Current CPI (May. 2026)
=0/335.1230*335.1230
=0.000

Current CPI (May. 2026) = 335.1230.

CNBX Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201608 0.120 240.849 0.167
201611 -0.120 241.353 -0.167
201702 -0.120 243.603 -0.165
201705 -0.240 244.733 -0.329
201708 -0.960 245.519 -1.310
201711 -0.480 246.669 -0.652
201802 -1.680 248.991 -2.261
201805 -0.840 251.588 -1.119
201808 -0.720 252.146 -0.957
201811 -0.600 252.038 -0.798
201902 7.800 252.776 10.341
201905 -4.800 256.092 -6.281
201908 0.120 256.558 0.157
201911 -4.560 257.208 -5.941
202002 -0.600 258.678 -0.777
202005 -6.000 256.394 -7.842
202008 -6.000 259.918 -7.736
202011 -0.600 260.229 -0.773
202102 -0.480 263.014 -0.612
202105 -1.170 269.195 -1.457
202108 -0.190 273.567 -0.233
202111 -1.200 277.948 -1.447
202202 -1.010 283.716 -1.193
202205 -0.550 292.296 -0.631
202208 -0.940 296.171 -1.064
202211 -0.330 297.711 -0.371
202302 -1.330 300.840 -1.482
202305 -0.020 304.127 -0.022
202308 -0.025 307.026 -0.027
202311 -0.006 307.051 -0.007
202402 -0.010 310.326 -0.011
202405 0.000 314.069 0.000
202408 0.000 314.796 0.000
202411 -0.001 315.493 -0.001
202502 0.000 319.082 0.000
202505 0.000 321.465 0.000
202508 0.000 323.976 0.000
202511 0.000 324.122 0.000
202602 0.000 326.785 0.000
202605 0.000 335.123 0.000

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $0.00 mean?
CNBX Pharmaceuticals (CNBX) has a E10 of $0.00 as of May. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on CNBX Pharmaceuticals and its competitors.
Is CNBX Pharmaceuticals' E10 too high?
CNBX Pharmaceuticals' current E10 is $0.00.
How does CNBX Pharmaceuticals' E10 compare to SIGY and LIPO?
CNBX Pharmaceuticals' E10 of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on CNBX Pharmaceuticals and its competitors. CNBX Pharmaceuticals's current E10 is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNBX Pharmaceuticals stock overvalued right now?
CNBX Pharmaceuticals (CNBX) has a current E10 of $0.00. The current E10 is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For CNBX Pharmaceuticals (CNBX), the current E10 is $0.00 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CNBX Pharmaceuticals Business Description

Address No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.